Developer docs
API playgroundTry for free, no card

Search company profiles

Synthon

Full company profile

uuid00072jp

Namestring
Synthon
Legal namestring
Synthon International Holding B.V.
Websiteurl
synthon.com
Company typeenum
Private
Founded yearint
1991
Descriptiontext

Synthon is a Netherlands-headquartered pharmaceutical company specializing in the development, manufacturing, and commercialization of complex generic medicines. Founded in 1991 and headquartered in Nijmegen, Synthon operates primarily as a Business-to-Business platform for the global generics industry, out-licensing and supplying its products to pharmaceutical partners worldwide rather than building consumer-facing brands — with limited exceptions in Mexico and Chile where it commercializes directly under the Synthon brand. The company is privately held under majority ownership of Goldman Sachs Alternatives, which acquired the stake from BC Partners in June 2025 in a transaction valuing the company at approximately €2 billion.

Short descriptiontext

Synthon is a Dutch pharmaceutical company that develops, manufactures, and out-licenses complex generic medicines to global pharmaceutical partners across six countries, with a portfolio of over 50 products spanning oncology, CNS, and cardiovascular therapeutics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersNijmegen, Netherlands
HQ citystring
Nijmegen
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
complex generic medicines, active pharmaceutical ingredients, pharmaceutical out-licensing, drug product manufacturing, pharmaceutical development services
Industry4 codes
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Medicinal Chemicals & Botanical Products2833
Product category
Generic Pharmaceuticals
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Generic medicines development and manufacturing
TypeOne Time License
Description

Synthon develops, manufactures, and commercializes complex generic pharmaceuticals globally. The company operates through a B2B model, serving as a development engine for the generics industry by providing partners with high-quality generic medicines.

synthon.com
2Direct-to-market sales
TypeOne Time License
Description

In select markets such as Mexico and Chile, Synthon increases access to affordable medicines under the Synthon brand through direct-to-market sales operations.

synthon.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Synthon develops, manufactures, and commercializes complex generic pharmaceuticals globally, operating primarily as a B2B development engine that out-licenses and supplies generic medicines to pharmaceutical partners. Its portfolio spans more than 50 products across oncology, central nervous system, cardiovascular, musculoskeletal, urology, allergy, surgery-support, and systemic therapeutic areas, supported by vertically integrated API and drug-product manufacturing across Europe and Latin America. In select markets (Mexico, Chile), Synthon also sells directly under its own brand.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Synthon is a leading pharmaceutical company specialized in the development, manufacturing, and commercialization of complex generic pharmaceuticals globally. The company's product portfolio comprises over 50 generic medicines spanning multiple therapeutic areas including Oncology (Abiraterone, Anagrelide, Anastrozole, Bendamustine, Bicalutamide, Bortezomib, Dasatinib, Erlotinib, Everolimus, Exemestane, Gefitinib, Imatinib, Lenalidomide, Letrozole, Pemetrexed, Pomalidomide, Sunitinib, Zoledronic Acid), Central Nervous System (Aripiprazole, Clozapine, Dimethyl Fumarate, Donepezil, Fingolimod, Fluvoxamine, Glatiramer, Memantine, Paroxetine, Rasagiline, Zolpidem, Zopiclone), Cardiovascular (Bisoprolol, Eltrombopag, Eplerenone, Ivabradine, Simvastatin), Musculoskeletal System (Celecoxib, Etoricoxib, Ibandronate), Urology (Doxazosin, Sevelamer, Solifenacin-Tamsulosin, Tadalafil, Tamsulosin), Allergy (Levocetirizine, Montelukast), Surgery Support (Flumazenil, Sugammadex), and Systemic conditions (Cinacalcet, Deferasirox, Voriconazole). The company operates with a Business-to-Business model, primarily serving as a development engine and partner for pharmaceutical companies seeking complex generic medicines.

Product and service1 record
1Abiraterone
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA) for the U.S. market. Synthon has a pending abbreviated new drug application (ANDA) seeking approval for relapsing forms of multiple sclerosis treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-01
Description

Exclusive development, licensing, supply and commercialization agreement for a novel 505(b)(2) oncology product for the U.S. market.

Strategic tierMinorTypeOthersAnnounced on2024-07-01
Description

Logistics partnership for expanded distribution services in Chile. Kuehne+Nagel provides distribution services to support Synthon's operations in the region.

Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-12-01
Description

Partnership with Saudi-based SAJA to commercialize several products in the MENA (Middle East and North Africa) region. SAJA is a joint venture between Tamer Industries and Japanese pharmaceutical companies Daiichi Sankyo and Astellas Pharma.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

World's largest generic pharmaceutical manufacturer with broad small-molecule generics portfolio and API manufacturing. Direct competitor in complex generics across oncology, CNS, and cardiovascular categories where Synthon also competes, with overlapping B2B supply and out-licensing models.

TypeDirect peer
Description

Canadian privately-held generic pharmaceutical manufacturer with vertically integrated API and finished-dose capabilities across oncology, CNS, and cardiovascular. Comparable as a privately-held, vertically integrated complex generics developer with significant out-licensing activity.

TypeDirect peer
Description

Formed from Mylan-Upjohn merger, Viatris is a major global generics player with significant complex generics, biosimilars, and API exposure. Comparable product breadth across oncology, CNS, and cardiovascular, with global commercial reach that exceeds Synthon's direct footprint.

TypeDirect peer
Description

Jordan-headquartered specialty generic and injectable pharmaceutical manufacturer with significant U.S. and MENA presence. Comparable to Synthon's injectable complex generics portfolio (Bortezomib, Bendamustine, Pemetrexed) and its MENA distribution via SAJA.

TypeEmerging player
Description

Iceland-based biosimilars developer with vertically integrated manufacturing focused on complex biologics. Comparable to Synthon as a vertically integrated complex-medicines platform leveraging technical barriers and partner-led commercialization in regulated markets.

TypeDirect peer
Description

India-based global pharmaceutical company with a complex generics and specialty pipeline, including injectables and inhalation products. Comparable to Synthon's complex generics development engine and out-licensing approach in regulated markets.

TypeDirect peer
Description

India-headquartered integrated pharmaceutical company with a strong complex generics portfolio, including injectables and biosimilars, and significant U.S. out-licensing and partnership activity. Comparable on technical complexity, vertical integration, and B2B commercial model.

TypeDirect peer
Description

Indian generic pharmaceutical manufacturer with vertically integrated API-to-finished-product operations and a broad complex generics portfolio. Comparable on manufacturing scale, cost competitiveness, and broad therapeutic-area generics coverage overlapping with Synthon's portfolio.

TypeDirect peer
Description

European-headquartered generics and specialty pharma group, currently owned by Bain Capital and Cinven. Closely comparable to Synthon as a PE-owned complex generics platform with a B2B/partnership commercialization model and a focus on differentiated generics across multiple therapeutic areas.

10Sandoz
TypeDirect peer
Description

Novartis-spin global generics and biosimilars leader with vertically integrated manufacturing and a strong complex generics pipeline. Closely comparable business model to Synthon with European heritage, broad therapeutic-area coverage, and focus on hard-to-make generics and biosimilars.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Synthon

Generic Pharmaceuticalssynthon.com

Synthon is a Dutch pharmaceutical company that develops, manufactures, and out-licenses complex generic medicines to global pharmaceutical partners across six countries, with a portfolio of over 50 products spanning oncology, CNS, and cardiovascular therapeutics.

What Synthon does

Synthon is a Netherlands-headquartered pharmaceutical company specializing in the development, manufacturing, and commercialization of complex generic medicines. Founded in 1991 and headquartered in Nijmegen, Synthon operates primarily as a Business-to-Business platform for the global generics industry, out-licensing and supplying its products to pharmaceutical partners worldwide rather than building consumer-facing brands — with limited exceptions in Mexico and Chile where it commercializes directly under the Synthon brand. The company is privately held under majority ownership of Goldman Sachs Alternatives, which acquired the stake from BC Partners in June 2025 in a transaction valuing the company at approximately €2 billion.

Synthon firmographics

Firmographics
Name
Synthon
Legal name
Synthon International Holding B.V.
Website
https://synthon.com
Company type
Private
Founded year
1991
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Synthon is a Dutch pharmaceutical company that develops, manufactures, and out-licenses complex generic medicines to global pharmaceutical partners across six countries, with a portfolio of over 50 products spanning oncology, CNS, and cardiovascular therapeutics.
Ownership category
akta.pro rank

Synthon industry classification

Industry
Product category
Generic Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIABAG
Generic APIs & Intermediates (Active Ingredients)
SECONDARYHLAIABAJ
Generic ANDA/Regulatory Affairs & Submissions

Keywords

  • Complex generic medicines
  • Active pharmaceutical ingredients
  • Pharmaceutical out-licensing
  • Drug product manufacturing
  • Pharmaceutical development services

Where Synthon is headquartered

Location

Headquarters

HQ city
Nijmegen
HQ country
Netherlands
HQ region
Europe

Offices6 records

Markets served

Synthon business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Generic medicines development and manufacturing: Synthon develops, manufactures, and commercializes complex generic pharmaceuticals globally. The company operates through a B2B model, serving as a development engine for the generics industry by providing partners with high-quality generic medicines.
  2. Direct-to-market sales: In select markets such as Mexico and Chile, Synthon increases access to affordable medicines under the Synthon brand through direct-to-market sales operations.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Synthon product offering

Product offering

Core offering

Synthon develops, manufactures, and commercializes complex generic pharmaceuticals globally, operating primarily as a B2B development engine that out-licenses and supplies generic medicines to pharmaceutical partners. Its portfolio spans more than 50 products across oncology, central nervous system, cardiovascular, musculoskeletal, urology, allergy, surgery-support, and systemic therapeutic areas, supported by vertically integrated API and drug-product manufacturing across Europe and Latin America. In select markets (Mexico, Chile), Synthon also sells directly under its own brand.

Product overview

Synthon is a leading pharmaceutical company specialized in the development, manufacturing, and commercialization of complex generic pharmaceuticals globally. The company's product portfolio comprises over 50 generic medicines spanning multiple therapeutic areas including Oncology (Abiraterone, Anagrelide, Anastrozole, Bendamustine, Bicalutamide, Bortezomib, Dasatinib, Erlotinib, Everolimus, Exemestane, Gefitinib, Imatinib, Lenalidomide, Letrozole, Pemetrexed, Pomalidomide, Sunitinib, Zoledronic Acid), Central Nervous System (Aripiprazole, Clozapine, Dimethyl Fumarate, Donepezil, Fingolimod, Fluvoxamine, Glatiramer, Memantine, Paroxetine, Rasagiline, Zolpidem, Zopiclone), Cardiovascular (Bisoprolol, Eltrombopag, Eplerenone, Ivabradine, Simvastatin), Musculoskeletal System (Celecoxib, Etoricoxib, Ibandronate), Urology (Doxazosin, Sevelamer, Solifenacin-Tamsulosin, Tadalafil, Tamsulosin), Allergy (Levocetirizine, Montelukast), Surgery Support (Flumazenil, Sugammadex), and Systemic conditions (Cinacalcet, Deferasirox, Voriconazole). The company operates with a Business-to-Business model, primarily serving as a development engine and partner for pharmaceutical companies seeking complex generic medicines.

Differentiator

Problem solved

Functional benefit

Products and services

  • Abiraterone

Companies that use Synthon

Customer profile

Segments1 record

Ideal customer profiles2 records

Synthon technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Synthon partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, minor and strategic.

  • Zydus LifesciencescoreStrategic or Co-development Partner · 1 September 2025Exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA) for the U.S. market. Synthon has a pending abbreviated new drug application (ANDA) seeking approval for relapsing forms of multiple sclerosis treatment.
  • Zydus Lifesciences (505(b)(2) partnership)coreStrategic or Co-development Partner · 1 February 2025Exclusive development, licensing, supply and commercialization agreement for a novel 505(b)(2) oncology product for the U.S. market.
  • Kuehne+NagelminorOthers · 1 July 2024Logistics partnership for expanded distribution services in Chile. Kuehne+Nagel provides distribution services to support Synthon's operations in the region.
  • SAJA PharmaceuticalsstrategicChannel Partner/ Reseller/ Distributor · 1 December 2022Partnership with Saudi-based SAJA to commercialize several products in the MENA (Middle East and North Africa) region. SAJA is a joint venture between Tamer Industries and Japanese pharmaceutical companies Daiichi Sankyo and Astellas Pharma.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Synthon competitors and assessment

Company assessment

Direct peers

  • Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with broad small-molecule generics portfolio and API manufacturing. Direct competitor in complex generics across oncology, CNS, and cardiovascular categories where Synthon also competes, with overlapping B2B supply and out-licensing models.
  • Apotex: Canadian privately-held generic pharmaceutical manufacturer with vertically integrated API and finished-dose capabilities across oncology, CNS, and cardiovascular. Comparable as a privately-held, vertically integrated complex generics developer with significant out-licensing activity.
  • Viatris: Formed from Mylan-Upjohn merger, Viatris is a major global generics player with significant complex generics, biosimilars, and API exposure. Comparable product breadth across oncology, CNS, and cardiovascular, with global commercial reach that exceeds Synthon's direct footprint.
  • Hikma Pharmaceuticals: Jordan-headquartered specialty generic and injectable pharmaceutical manufacturer with significant U.S. and MENA presence. Comparable to Synthon's injectable complex generics portfolio (Bortezomib, Bendamustine, Pemetrexed) and its MENA distribution via SAJA.
  • Lupin Limited: India-based global pharmaceutical company with a complex generics and specialty pipeline, including injectables and inhalation products. Comparable to Synthon's complex generics development engine and out-licensing approach in regulated markets.
  • Dr. Reddy's Laboratories: India-headquartered integrated pharmaceutical company with a strong complex generics portfolio, including injectables and biosimilars, and significant U.S. out-licensing and partnership activity. Comparable on technical complexity, vertical integration, and B2B commercial model.
  • Aurobindo Pharma: Indian generic pharmaceutical manufacturer with vertically integrated API-to-finished-product operations and a broad complex generics portfolio. Comparable on manufacturing scale, cost competitiveness, and broad therapeutic-area generics coverage overlapping with Synthon's portfolio.
  • Stada Arzneimittel: European-headquartered generics and specialty pharma group, currently owned by Bain Capital and Cinven. Closely comparable to Synthon as a PE-owned complex generics platform with a B2B/partnership commercialization model and a focus on differentiated generics across multiple therapeutic areas.
  • Sandoz: Novartis-spin global generics and biosimilars leader with vertically integrated manufacturing and a strong complex generics pipeline. Closely comparable business model to Synthon with European heritage, broad therapeutic-area coverage, and focus on hard-to-make generics and biosimilars.

Emerging players

  • Alvotech: Iceland-based biosimilars developer with vertically integrated manufacturing focused on complex biologics. Comparable to Synthon as a vertically integrated complex-medicines platform leveraging technical barriers and partner-led commercialization in regulated markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Synthon social profiles

Digital presence

Synthon compliance and trust

Trust signal

Compliance1 record

Synthon financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Synthon leadership team

Management profile

Number of profiles

Profiles5 records

Synthon subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Synthon funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Synthon M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Synthon

What does Synthon do?

Synthon develops, manufactures, and commercializes complex generic pharmaceuticals globally, operating primarily as a B2B development engine that out-licenses and supplies generic medicines to pharmaceutical partners. Its portfolio spans more than 50 products across oncology, central nervous system, cardiovascular, musculoskeletal, urology, allergy, surgery-support, and systemic therapeutic areas, supported by vertically integrated API and drug-product manufacturing across Europe and Latin America. In select markets (Mexico, Chile), Synthon also sells directly under its own brand.

Is Synthon a public or private company?

Synthon is a private company. It is classified as private equity controlled and is currently operating.

When was Synthon founded?

Synthon was founded in 1991. It employs 1,001 to 5,000 people.

Where is Synthon based?

Synthon is headquartered in Nijmegen, Netherlands, in the Europe region.

How does Synthon make money?

Two revenue lines are on record. Generic medicines development and manufacturing is the primary driver. The others are direct-to-market sales.

Who are Synthon's main competitors?

Direct peers on record are Teva Pharmaceutical Industries, Apotex, Viatris, Hikma Pharmaceuticals, Lupin Limited, Dr. Reddy's Laboratories, Aurobindo Pharma, Stada Arzneimittel and Sandoz. Alvotech is listed as an emerging player.

Does Synthon have an API?

No public API is recorded for Synthon.

What industry is Synthon in?

Synthon's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Times of Indiazydus lifesciences: Zydus ties up with Synthon BV for multiple sclerosis drug launch in US - The Economic TimesZydus Lifesciences, through its subsidiary Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV to launch Ozanimod capsules, a generic version of Bristol Myers Squibb's ZEPOSIA, for treating relapsing forms of multiple sclerosis in the US market. Synthon will handle regulatory approval and product manufacturing, while Zydus will be responsible for commercialization in the United States. The total addressable market for this drug in the US is estimated at USD 637 million as per IQVIA data.PR NewswireZydus and Synthon entered into exclusive licensing and supply agreement for Ozanimod Capsules (generic version of ZEPOSIA®) for the U.S. marketZydus Lifesciences, through its wholly owned subsidiary Zydus Lifesciences Global FZE, has entered into an exclusive licensing and supply agreement with Netherlands-based Synthon BV for Ozanimod Capsules, a generic version of Bristol Myers Squibb's ZEPOSIA®, for the U.S. market. Under the agreement, Synthon will handle regulatory approval, manufacturing, and supply of the product, while Zydus will be responsible for commercialization in the USA, with the product having received tentative FDA approval and eligibility for 180-day shared exclusivity. The total addressable market for Ozanimod Capsules in the U.S. is approximately US $637 million as of IQVIA MAT July 2025.The Times of IndiaZydus Lifesciences in pact with Synthon for specialty oncology product in US - The Economic TimesZydus Lifesciences has signed an exclusive development, licensing, supply, and commercialisation agreement with Dutch drugmaker Synthon for a novel 505(B)(2) oncology product targeting an undisclosed indication. Under the terms, Synthon will handle development, manufacturing, and supply while Zydus will be responsible for New Drug Application submission and commercialisation in the United States, with filing expected in 2026. According to IQVIA MAT data for December 2024, the reference product's addressable market size is approximately $1.5 billion.openPR.comGlobal Biosimilars Market: Emerging Trends, Major Key Players Novartis (Sandoz) and Synthon Pharmaceuticals, IncThe global biosimilars market is projected to reach $66.21 billion by 2028, growing at a 24.27% CAGR from 2021 to 2028. Growth is driven by rising prevalence of inflammatory disorders, biotech innovation, and increased R&D spending. Key players include Novartis (Sandoz), Synthon, Teva, and LG Life Science.PR NewswireMylan and Development Partner, Synthon, Win Significant European Patent Office Ruling Related to Copaxone® 40mg/mLThe European Patent Office's Technical Board of Appeal ruled that Yeda Research and Development Company's patent related to Teva's Copaxone 40 mg/mL product is invalid, a decision Mylan N.V. and Synthon secured through their legal challenge. This ruling allows Mylan to immediately return to the market and accelerate the commercialization of its lower-cost generic version of the multiple sclerosis treatment across Europe. The victory marks another significant step in Mylan's long-standing legal battle against Teva to expand patient access to affordable alternatives.Business Wire BlogSynthon Biopharmaceuticals Relaunches as ByondisSynthon Biopharmaceuticals is relaunching as Byondis, an independent biopharmaceutical company developing precision medicines for cancer and autoimmune diseases. Its pipeline includes the anti-HER2 ADC SYD985, with a Phase III trial expected to report results in the second half of 2020. The company plans to enter the clinic with four additional programs in 2020/2021.PR NewswireMylan, in Partnership with Synthon, Receives Marketing Authorization Approval in Europe for First Generic for Copaxone® 40 mg/mLMylan N.V., in partnership with Synthon, received marketing authorization approval in Europe for Glatiramer Acetate Injection 40 mg/mL, a generic version of Teva's Copaxone 40 mg/mL for treating relapsing forms of multiple sclerosis. This approval marks the first generic authorization for this specific dosage strength in European markets. Mylan holds exclusive distribution and supply rights for the product across 17 European countries including Germany, France, Spain, Italy, the United Kingdom, and the Netherlands.